Arnab Basu, the chief executive officer of (), tells Proactive they've seen a solid increase in revenue in the six months to the end of October.
Revenue rose 27% to £4.8mln from £3.8mln the year before, leading to a significant narrowing of underlying losses (LBITDA) to £0.3mln from a loss the year before of £0.6mln.
The company is targeting break-even at the EBITDA level and remains on course to achieve this.
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event,
London , 24 January 2019.
Register here »